RTP Mobile Logo

Interview with Prof Eric Van Cutsem, MD, PhD

Track 1: Biomarker assessment for patients with metastatic colorectal cancer (mCRC) in the first-line setting
Track 2: Identification and therapeutic implications of rare genetic alterations for patients with mCRC
Track 3: Effect of primary tumor sidedness on clinical decision-making for mCRC
Track 4: Benefit with EGFR antibodies as first-line therapy for patients with mCRC and left-sided tumors
Track 5: Sequencing therapies for patients with KRAS wild-type mCRC who have right-sided tumors
Track 6: Selection of therapy for patients with mCRC according to KRAS mutation status
Track 7: Therapeutic approach to mCRC with BRAF mutations
Track 8: Side effects associated with BRAF/MEK inhibitors in combination with EGFR antibodies
Track 9: Incidence and detection of HER2 amplifications in patients with mCRC
Track 10: Management of HER2-amplified mCRC
Track 11: Efficacy and tolerability of TAS-102 for mCRC
Track 12: Efficacy and tolerability of regorafenib in the Phase II Regorafenib Dose Optimization Study (ReDOS)
Track 13: Clinical implications of tumor cavitation induced by regorafenib
Track 14: Phase II TASCO1 study evaluating the combination of TAS-102 or capecitabine with bevacizumab as first-line treatment for unresectable mCRC
Track 15: Biology of microsatellite instability-high colorectal cancer and response to immune checkpoint inhibitors
Track 16: Efficacy of anti-PD-1 antibodies as monotherapy or in combination with anti-CTLA-4 antibodies
Track 17: Side effects associated with immune checkpoint inhibitors
Track 18: Potential role of immune checkpoint inhibitors in combination with chemotherapy
Track 19: Predictors of benefit with immune checkpoint inhibitors in CRC
Track 20: Novel agents and approaches under investigation in the management of CRC
Eric Van Cutsem, MD, PhD
Professor of Medicine
Digestive Oncology
University Hospital Gasthuisberg/Leuven
Leuven, Belgium
Neil Love, MD
Research To Practice
Miami, Florida